Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred patients, aged between 60 and 92 years, were treated with tiapride for neurological disorders (abnormal movements, buccofacial dyskinesias, dopa therapy complications, ballism, eyelid tics, senile tremor, post-traumatic headache, delirium tremens), psychiatric disorders with more or less marked agitation and of various types (hysteria, depression, mood disturbances, hypochondria, delusions, hallucinations), or for mental deficiency, senile dementia, or arteriopathic dementia. Results were excellent, being satisfactory in 70 p. cent, and even more marked in some groups. Tolerance was very good, with some rare cases of somnolence. The efficacy and safety of tiapride makes it of particular value for treating neuropsychiatric disorders in geriatric patients.
Sem Hop
PMID:[Tiapride in the treatment of neurological and psychiatric disorders in the elderly (author's transl)]. 627 32

All depressive syndromes include physical as well as psychological features. Physical symptoms in major "endogenous" depression are well known. In other forms, called masked depressions, various physical disorders are the patients main complaint and may be misleading. Localized pain and paresthesia are common. Behaviour disorders may mask depression in adolescents. Mood disturbances (loss of interest, anhedonia) as well as the personal and family histories, should be precisely assessed in order to establish diagnosis. Masked depression is not a minor form of depressive syndrome and antidepressant drugs should be used in correct doses over a sufficient period of time.
Sem Hop
PMID:[Masked depression and paucisymptomatic depression (author's transl)]. 627 36

Tiapride was used in 55 chronic alcoholics. It has a sedative effect on the anxiety, aggressiveness and agitation observed during the alcohol withdrawal syndrome. It is also effective against tremor, insomnia and fatigue. Fatigue or depression do not occur as side-effects. Tiapride induces a psychological feeling of wellbeing which is heightened by continuation of detoxication and general management.
Sem Hop
PMID:[Tiapride in detoxication of chronic alcoholics (author's transl)]. 627 32

We studied a case of surgical menopause in a hysterical patient. Castration was followed by depression with sexual disorders, somatic complaints, and specific menopausal manifestations, mainly hot flushes. Hysterectomy had been done a year earlier. Since then the patient had been admitted twice to a psychiatric ward following attempted suicide. Veralipride was given for twenty days. Noticeable improvement was recorded. Therapy was then discontinued for ten days. Symptoms recurred and long-lasting therapy was decided on. Subsequently, sustained overall improvement with disappearance of specific menopausal disorders, were recorded.
Sem Hop 1982 Jan 14
PMID:[Intractable menopausal disorders cured by veralipride (author's transl)]. 627 94

Menopausal complaints, especially hot flushes, are common occurrences. Until now, no effective treatment was available for patients in whom estrogens are contraindicated. A trial of veralipride was carried out in ten symptomatic menopausal women (7 physiologic menopauses, 3 surgical menopauses). Symptoms included severe hot flushes, anxiety (N = 6), depression (N = 4), irritability (N = 3), and cephalalgia (N = 2). Patients were given one tablet of veralipride each day for twenty day periods. Effectiveness on hot flushes was excellent in six patients, satisfactory in two, mediocre in one, and null in one. Depression, anxiety, and, to a lesser extent, cephalalgia and irritability, were alleviated. No clinical or biological adverse side-effects were recorded.
Sem Hop 1982 Feb 18
PMID:[A clinical trial of veralipride in menopausal complaints (author's transl)]. 628 Mar 13

Depression and Parkinson disease, two very different conditions at first sight, have much more intricate connections than is usually believed. Depression may be the patient's reaction to Parkinson disease, a condition that is anticipated with anxiety, with good reason as it is often very disabling and has not been significantly prolonged by dopamine therapy. Depression may precede the first signs of Parkinson disease. Pseudoparkinsonian melancholia may be difficult to distinguish from the akinetic form of Parkinson disease. Most of the symptoms of the latter have been encountered in the former. The following features do not occur in depression: astasia with trepidation, festination, monotonous tachyphemia and palilalia, sebaceous hypersecretion, and of course unilateral or frankly asymmetric signs. Parkinson syndrome secondary to depression can be classified with those parkinsonian syndromes that are different from parkinson disease and secondary to a clearcut etiology. In some instances, diagnosis is established by the response to therapy. In the present state of our knowledge, the treatment of depression relies on chemotherapy and sismotherapy and not on dopamine therapy. The management of Parkinson disease rests on dopamine which may be associated with tricylic antidepressants.
Sem Hop 1982 Apr 08
PMID:[Parkinson disease and depression (author's transl)]. 628 98

Twenty-five patients with various forms of dyskinesia were given tiapride for three months. Maximal dosage was 900 mg per day. A double-blind trial of tiapride versus placebo showed significantly better results in the group given tiapride. The forms of dyskinesia which responded best to tiapride were the following: iatrogenic dyskinesia, tics (Gilles de la Tourette syndrome), and chronic chorea (Huntington disease). Patients with complex dyskinesia resulting from neonatal encephalopathy or vascular disease were not improved. The protocol used in l-dopa-induced dyskinesia is described. Changes in dyskinesia and "on-off" effect following variations in tiapride and l-dopa dosage are detailed. An unequivocal, although minor, tiapride-induced parkinson syndrome was recorded in a few patients. No instances of tiapride-induced dyskinesia or akathisia were seen. The other side-effects were either psychic (depression, drowsiness, agitation) or endocrinologic (menstrual disorders, overeating, galactorrhea).
Sem Hop 1982 Mar 25
PMID:[Clinical trial of tiapride in patients with dyskinesia (author's transl)]. 628 45

The authors report on two years of their experience in caring for alcoholics after withdrawal. In evaluating results, improvements in asthenia, depression, and anxiety, as well as in the aptitude to resume a normal life, with satisfactory familial, conjugal, sexual, professional and social achievements, are considered. Overall results are given in terms of abstinence, relapse, hospitalization, and normalization of behavior and character.
Sem Hop 1982 Oct 07
PMID:[The alcoholic in the post-withdrawal periods. Conditions of their care and results after 2 years. Apropos of 200 cases]. 629 41

The neuropsychiatric manifestations of alcoholism can be amended by neutralizing the somatic effects of alcohol on nervous centers. Tiapride acts electively on the mesolimbic area. Promising results have been obtained with tiapride in the various clinical forms of alcohol intoxication. Sixty patients (40 men and 20 women) were given tiapride for abnormal symptoms due to alcohol. Tolerance was good: no side-effects were recorded, with the exception of extrapyramidal manifestations in one patient. Symptoms due to alcohol abuse were alleviated. Relief of tremor was significant. Tiapride proved helpful in anxiety and depression and caused hallucinations to disappear in 35 cases.
Sem Hop 1982 Dec 16
PMID:[Treatment of alcoholic patients with tiapride]. 629 73

Veralipride was given to two patients with early menopause ascertained by hormonal investigations. In both women (aged 33 and 30 years), an estradiol-progestogen combination given for hot flushes, disorders of character, and depression, had been unsuccessful. Symptoms resolved under therapy with veralipride alone or associated with the previous treatment. In one patient, symptoms recurred after veralipride was discontinued and resolved again once the drug was resumed.
Sem Hop 1983 Jan 06
PMID:[Treatment of early menopause. A report of 2 cases]. 629 87


<< Previous 1 2 3 4 5 Next >>